DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/df2sfp/a_competitive) has announced the addition of the "A Competitive Analysis of the Global Breast Cancer Therapeutics Market" report to their offering.
The study assesses marketed and investigational products and combination regimens for the global breast cancer therapeutics market. Segmentation by drug class is provided, along with supporting information, such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. Marketed and pipeline products are broadly segmented into hormonal therapy, targeted therapy, chemotherapy, and other therapies of current global interest. A large number of products in clinical development and the rising demand for breast cancer therapeutics are the key market drivers.
The global breast cancer therapeutics market is divided into segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).
About hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective oestrogen receptor modulators (SERMs).
Only approved targeted treatments are available in the U.S. market, namely, Herceptin (Roche) and Tykerb (GSK). 2 more drugs, Kadcyla (Roche) and Perjeta (Roche), were approved in 2013. At present, Roche dominates the global breast cancer therapeutics market.
Although there are approximately drugs indicated for the treatment of breast cancer, there remains a large unmet need to treat patients. As a result, the breast cancer pharmaceutical pipeline is strong, with about drugs in development.
Chemotherapy remains the most important class of drugs for breast cancer treatment; however, the trend of using targeted drugs is on the rise.
Combination treatment is a focus for companies with breast cancer treatment in development; however, drugs that held potential in Phase 2 trials failed to make an impact in Phase 3, forcing companies to re- design trials or stop the research programme.
Between 2015 and 2017, the key drugs to watch out for will be ABT-888 (AbbVie), NeuVax (Galena Biopharma), Palbociclib (Pfizer), NKTR-102 (Nektar), Nexavar (Bayer/Onyx), and CT-P6 (Celltrion).
Key Topics Covered:
1. Executive Summary
- Executive Summary
- Physician Guidelines to Breast Cancer Therapy-Her 2 Positive
- Physician Guidelines to Breast Cancer Therapy-ER or PR Positive
- Physician Guidelines to Breast Cancer Therapy-Triple-negative Breast Cancer
- Key Trends
- Market Opportunities
- Companies to Watch
2. Executive Summary
3. Market Overview
- Market Overview-Introduction
- Market Overview-Incidence Rate of Breast Cancer
- Market Size
- Market Segmentation
4. Competitive Landscape-Breast Cancer Marketed Products and Pipeline Candidates
- Competitive Landscape Overview
- Competitive Landscape-Breast Cancer Marketed and Pipeline Products
- Marketed Products-Hormone Therapy
- Marketed Products-Targeted Therapy
- Marketed Products-Chemotherapy
- Pipeline Products-Chemotherapy
- Pipeline Products-Other Therapies
- Product Launch Timeline
- Patent Expirations
5. Pivotal Phase 3 Trials
- Breast Cancer Therapeutics-Major Ongoing/Recently Completed Clinical Trials
- Summary of Key Products to Watch
6. Product Dashboard (Marketed Products and Phase 3 Candidates)
- Product Dashboard-Herceptin (Trastuzumab)
- Product Dashboard-Afinitor (Everolimus)
- Product Dashboard-Arimidex (Anastrozole)
- Product Dashboard-Perjeta (Pertuzumab)
- Product Dashboard-Tykerb (Lapatinib)
- Product Dashboard-Taxol (Paclitaxel)
- Product Dashboard-Xeloda (Capecitabine)
- Product Dashboard-Kadcyla (Ado-trastuzumab emtansine)
- Product Dashboard-PD-0332991(Palbociclib)
- Product Dashboard-NeuVax (Nelipepimut-S)
7. Conclusions
8. Appendix
For more information visit http://www.researchandmarkets.com/research/df2sfp/a_competitive
